Harrison SJ - Search Results

1

Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study.

Beer H, Chung H, Harrison SJ, Quach H, Taylor-Marshall R, Jones L, Krishnasamy M. Beer H, et al. Among authors: harrison sj. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):505-514. doi: 10.1016/j.clml.2023.03.008. Epub 2023 Apr 1. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37087351

2

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.

Prince HM, Bishton M, Harrison S. Prince HM, et al. Leuk Lymphoma. 2008 Mar;49(3):385-7. doi: 10.1080/10428190801950058. Leuk Lymphoma. 2008. PMID: 18297514

3

The development of novel immunotherapeutic approaches in multiple myeloma.

Peinert S, Prince HM, Harrison S. Peinert S, et al. Leuk Lymphoma. 2008 Apr;49(4):652-4. doi: 10.1080/10428190802007742. Leuk Lymphoma. 2008. PMID: 18398729 Review. No abstract available.

4

Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.

Harrison SJ, Franklin IM, Campbell JD. Harrison SJ, et al. Leuk Lymphoma. 2008 Dec;49(12):2272-83. doi: 10.1080/10428190802464729. Leuk Lymphoma. 2008. PMID: 19052974

5

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM. Quach H, et al. Leuk Lymphoma. 2009 Feb;50(2):223-9. doi: 10.1080/10428190802663213. Leuk Lymphoma. 2009. PMID: 19194832 Clinical Trial.

6

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Quach H, et al. Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Leukemia. 2010. PMID: 19907437 Free PMC article. Review.

7

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.

Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. Hsu AK, et al. Among authors: harrison sj. Blood. 2011 Feb 3;117(5):1605-13. doi: 10.1182/blood-2010-04-278432. Epub 2010 Oct 26. Blood. 2011. PMID: 20978269 Free article.

8

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. Harrison SJ, et al. Blood. 2011 Dec 8;118(24):6274-83. doi: 10.1182/blood-2011-03-339879. Epub 2011 Sep 12. Blood. 2011. PMID: 21911830 Free article. Clinical Trial.

9

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Joyce T, Harrison SJ. Doo NW, et al. Among authors: harrison sj. Leuk Lymphoma. 2013 Jul;54(7):1465-72. doi: 10.3109/10428194.2012.746682. Epub 2012 Dec 14. Leuk Lymphoma. 2013. PMID: 23121086

10

Myeloma and pregnancy: strange bedfellows?

Khot AS, Prince HM, Harrison SJ, Seymour JF. Khot AS, et al. Among authors: harrison sj. Leuk Lymphoma. 2014 Apr;55(4):966-8. doi: 10.3109/10428194.2013.837163. Epub 2013 Sep 9. Leuk Lymphoma. 2014. PMID: 23964646 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters